INDV — Indivior Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $3.97bn
- $4.23bn
- $1.24bn
Supernus soars on Indivior merger, Q2 revenue beat
Supernus, Indivior merge to strengthen neuroscience drug portfolio
Indivior Pharmaceuticals beats Q2 revenue on Sublocade growth, raises FY guidance
Indivior Pharmaceuticals Q1 revenue rises 19%, beats estimates
Focus: Drugmakers delay some European launches with a wary eye on Trump's pricing policies
Focus: Drugmakers delay some European launches with a wary eye on Trump's pricing policies
US STOCKS ON THE MOVE-Kyivstar Group, Applied Materials, Tevogen Bio
U.S. STOCKS ON THE MOVE-Carvana, Circle, Voyager Acquisition Corp
Indivior Pharma rebounds after upsized $450 mln convertible bond offering
Indivior Pharma slides after announcing $400 mln convertible bonds sale plans
Brief: Indivior Announces Proposed Convertible Senior Notes Offering
Brief: Indivior Concludes Legacy U.S. Department Of Justice Matter
Brief: Clinical Evidence Supports Rapid SUBLOCADE Induction As A Strategy To Improve Retention In Opioid Use Disorder Treatment
Brief: Indivior Proposes New Corporate Structure To Achieve U.S. Domiciliation
UK's Indivior to re-domicile to US after listing move
U.S. RESEARCH ROUNDUP-Colgate-Palmolive, McKesson, Microsoft